<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04261712</url>
  </required_header>
  <id_info>
    <org_study_id>CRN00808-05</org_study_id>
    <secondary_id>U1111-1245-5276</secondary_id>
    <secondary_id>2019-002193-31</secondary_id>
    <nct_id>NCT04261712</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)</brief_title>
  <official_title>An Open Label, Long-term Extension Study to Evaluate the Safety and Efficacy of CRN00808 in Subjects With Acromegaly (ACROBAT Advance)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crinetics Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Crinetics Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy&#xD;
      of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2&#xD;
      biased agonist) in subjects with acromegaly.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 29, 2019</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) throughout the study</measure>
    <time_frame>Week 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in insulin-like growth factor-1 (IGF-1) level</measure>
    <time_frame>Week 16, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in growth hormone (GH) level</measure>
    <time_frame>Week 16, Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Paltusotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paltusotine</intervention_name>
    <description>Paltusotine, capsules, once daily by mouth</description>
    <arm_group_label>Paltusotine</arm_group_label>
    <other_name>CRN00808</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Completed one of the parent studies (Acrobat Evolve [CRN00808-02] or Acrobat Edge&#xD;
             [CRN00808-03])&#xD;
&#xD;
          2. Females must be non-pregnant and non-lactating, and either surgically sterile,&#xD;
             post-menopausal, or using effective method(s) of birth control&#xD;
&#xD;
          3. Willing to provide signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant concomitant disease including, but not limited to,&#xD;
             cardiovascular disease; moderate or severe renal insufficiency; or significant liver&#xD;
             disease (including cirrhosis)&#xD;
&#xD;
          2. Pituitary radiation since completing participation in parent studies&#xD;
&#xD;
          3. History or presence of malignancy except adequately treated basal cell and squamous&#xD;
             cell carcinomas of the skin within the past 5 years&#xD;
&#xD;
          4. Positive test at Screening for HIV, hepatitis B surface antigen (HBsAg) or hepatitis C&#xD;
             antibody (HCV-Ab).&#xD;
&#xD;
          5. History of alcohol or substance abuse in the past 12 months&#xD;
&#xD;
          6. Use of any investigational drug (other than paltusotine) within the past 30 days or 5&#xD;
             half-lives, whichever is longer before Screening&#xD;
&#xD;
          7. Any condition that in the opinion of the investigator would jeopardize the subject's&#xD;
             appropriate participation in this study.&#xD;
&#xD;
          8. Cardiovascular conditions or medications associated with prolonged QT or those which&#xD;
             predispose subjects to heart rhythm abnormalities&#xD;
&#xD;
          9. Subjects with symptomatic cholelithiasis&#xD;
&#xD;
         10. Subjects with clinically significant abnormal findings during the Screening Period,&#xD;
             and any other medical condition(s) or laboratory findings that, in the opinion of the&#xD;
             Investigator, might jeopardize the subject's safety or ability to complete the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Northwest Pituitary Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Endocrinology Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Av. Agostinho Leao Junior, 306- Alto da Gloria</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80030-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal University of Rio de Janeiro</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>21941</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CPQuali Pesquisa Clinica</name>
      <address>
        <city>São Paulo</city>
        <zip>01228</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;G.Gennimatas&quot;</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Laiko&quot;</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Evangelismos&quot;</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hippokration General hospital of Thessaloniki</name>
      <address>
        <city>Thessaloníki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg Egeszsegtigyi Kozpont</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE ÁOK Belgyógyászati és Onkológiai Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pécsi Tudományegyetem Klinika Kozpont I. sz. Belgyogyaszati Klinika</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Naţional de Endocrinologie &quot;C.I. Parhon&quot;</name>
      <address>
        <city>Bucuresti</city>
        <zip>011863</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Endocrinology and Diabetology</name>
      <address>
        <city>Ľubochňa</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry and Warwickshire NHS Trust</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 6, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acromegaly</keyword>
  <keyword>ACROBAT</keyword>
  <keyword>ADVANCE</keyword>
  <keyword>Paltusotine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

